COSCIENS Biopharma Inc. (CSCI)
NASDAQ: CSCI · Real-Time Price · USD
2.500
-0.200 (-7.41%)
At close: Dec 20, 2024, 4:00 PM
2.600
+0.100 (4.00%)
After-hours: Dec 20, 2024, 4:00 PM EST
COSCIENS Biopharma Revenue
COSCIENS Biopharma had revenue of $1.87M in the quarter ending September 30, 2024, with 62,266.67% growth. This brings the company's revenue in the last twelve months to $4.83M, down -25.23% year-over-year. In the year 2023, COSCIENS Biopharma had annual revenue of $4.50M, down -20.25%.
Revenue (ttm)
$4.83M
Revenue Growth
-25.23%
P/S Ratio
n/a
Revenue / Employee
$402,833
Employees
12
Market Cap
8.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4.50M | -1.14M | -20.25% |
| Dec 31, 2022 | 5.64M | 380.00K | 7.22% |
| Dec 31, 2021 | 5.26M | 1.61M | 44.03% |
| Dec 31, 2020 | 3.65M | 3.12M | 586.47% |
| Dec 31, 2019 | 532.00K | -26.35M | -98.02% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aytu BioPharma | 79.76M |
| Evogene | 7.48M |
| QT Imaging Holdings | 4.04M |
| RedHill Biopharma | 3.71M |
| Applied DNA Sciences | 3.43M |
| BioCardia | 71.00K |
CSCI News
- 5 weeks ago - COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs - GlobeNewsWire
- 2 months ago - COSCIENS Biopharma Announces Change to Board of Directors - GlobeNewsWire
- 2 months ago - COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director - GlobeNewsWire
- 3 months ago - COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs - GlobeNewsWire
- 4 months ago - COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - GlobeNewsWire
- 4 months ago - COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results - GlobeNewsWire